Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease

NCT00032279 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Graft-vs-Host Disease

Interventions

DRUG: Visilizumab

Sponsor

Fred Hutchinson Cancer Center

Collaborators

[object Object]